Empagliflozin's Fuel Hypothesis: Not so Soon
- PMID: 27508868
- DOI: 10.1016/j.cmet.2016.07.018
Empagliflozin's Fuel Hypothesis: Not so Soon
Abstract
The EMPA-REG OUTCOME trial (Zinman et al., 2015) established cardioprotective effects of empagliflozin in high-risk diabetic patients, but the underlying mechanisms remain elusive. A recent hypothesis proposed that increased ketone oxidation contributed to the effect, but several caveats indicate that the role of myocardial ketone oxidation is far from clear.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment on
-
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical